Pfizer, BioNTech just days away from applying for EUA for COVID-19 vaccine

By Samantha Black, PhD, ScienceBoard editor in chief

November 18, 2020 -- Pfizer and BioNTech have passed another milestone in their effort to deliver a vaccine for the SARS-CoV-2 virus. The companies on November 18 reported that their BNT162b2 vaccine candidate has met safety milestones and that they plan to apply for an emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the product in the coming days.

BNT162b2 has met the safety milestones that are required by the FDA for an EUA to be issued, according to the company. Pfizer and BioNTech plan to submit a request within days to the FDA for an EUA based on the safety and efficacy data collected to date, as well as manufacturing data related to the quality and consistency of the vaccine.

This announcement regarding the intent to submit an EUA comes just one week after the companies announced the interim results of the phase III trial.

More results from the phase III clinical trial

The data indicate a vaccine efficacy rate of 95% in participants without prior SARS-CoV-2 infection, measured seven days after participants received a second dose. The primary objective was based on 170 cases of COVID-19, as specified in the study protocol, where 162 of the cases were observed in the placebo group and only eight cases were in the BNT162b2 group.

The phase III trial began on July 27 and has enrolled 43,661 participants to date, 41,135 of whom have received a second dose of the vaccine candidate as of November 13. Importantly, the company found that efficacy was consistent across age, gender, race, and ethnicity demographics. The observed efficacy for the vaccine in individuals over 65 years of age was 94%. There were 10 cases of severe COVID-19 in the trial, nine of which occurred in the placebo group.

The independent monitoring committee for the study has not reported any serious safety concerns related to the vaccine and the vaccine seems to be well-tolerated. The committee reported only rare cases of fatigue (3.8%) or headache (2%).

The companies plan to submit the vaccine data to other regulatory agencies around the world.

Pfizer and BioNTech expect to produce up to 50 million vaccine doses globally in 2020 and up to 1.3 billion doses by the end of 2021. Four of Pfizer's facilities are part of the manufacturing and supply chain, including facilities in St. Louis, MO; Andover, MA; Kalamazoo, MI; and Puurs, Belgium. BioNTech's German sites will also be leveraged for global supply.

Pfizer will leverage its experience in cold-chain infrastructure to distribute the vaccine around the world. The companies have developed specially designed, temperature-controlled thermal shippers that utilize dry ice to maintain temperature conditions of -70°C. The containers can be used as temporary storage units for 15 days by refilling them with dry ice. Each shipper contains a GPS-enabled thermal sensor to track the location and temperature of each vaccine shipment across preset routes leveraging Pfizer's distribution network.

Pfizer, BioNTech finalize supply deal with EU for COVID-19 vaccine
Pfizer and BioNTech, developers of BNT162b2, a messenger RNA-based SARS-CoV-2 vaccine candidate, have reached an agreement with the European Commission...
Pfizer, BioNTech tout positive results for COVID-19 vaccine
Pfizer and BioNTech have released results from a phase III clinical trial evaluating their messenger RNA-based vaccine candidate, BNT162b2, demonstrating...
EMA to review BioNTech, Pfizer's SARS-CoV-2 vaccine
The European Medicines Agency (EMA) has accepted rolling review of BioNTech and Pfizer's SARS-CoV-2 vaccine candidate BNT162b2 based on preclinical and...
Pfizer, BioNTech release preclinical data, talk with EU about COVID-19 vaccine
Preclinical data have demonstrated the ability of BNT162b2, Pfizer and BioNTech's COVID-19 vaccine, to protect against infection. The companies are also...
Early trials show potential of Pfizer COVID-19 vaccine
Pharmaceutical giant Pfizer is making progress on BNT162b1, a COVID-19 vaccine candidate that is undergoing development and for which the U.S. government...
Pfizer, BioNTech get $1.95B for SARS-CoV-2 vaccine
Pfizer and BioNtech have inked an agreement with the U.S. Department of Health and Human Services and the Department of Defense, as part of the federal...

Copyright © 2020 scienceboard.net


Conferences
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter